Survey Shows Parkinson's Patients Strongly Recommend Apomorphine Infusion Therapy

In a recent survey from the InfusON study, Parkinson’s patients shared positive feedback on using continuous subcutaneous apomorphine infusion (CSAI) therapy. Many patients quickly adapted to using the CSAI device, with 79% becoming comfortable with the setup, and 68% adjusting to wearing the device within two weeks. Most patients reported that CSAI became part of their daily routine, and 95% would recommend it to others. The survey highlighted that while the setup initially took longer than 10 minutes for most (74%), once patients adjusted, 89% could complete it in 5 to 10 minutes. Although 16% found the device uncomfortable at first, this did not lead to discontinuation. The study enrolled patients with Parkinson’s disease who were already using levodopa but were still experiencing motor fluctuations. The results showed that patients who began CSAI therapy experienced significant reductions in OFF time (periods when medication is not working), with 61% meeting the response criteria by the start of the maintenance period, and these improvements were sustained for 52 weeks. Overall, the survey reinforces that CSAI is effective in managing motor fluctuations in Parkinson’s disease and is well-tolerated by patients. The ease of integrating it into daily routines has made it a valuable option for those seeking better control of their symptoms.